Improved therapeutic efficacy in two mouse models of methylmalonic acidemia (MMA) using a second-generation mRNA therapy

• Published in: Molecular genetics and metabolism Vol. 143; no. 1-2; p. 108560
• Main Authors: Coughlan, Kimberly A., Eybye, Marianne, Henderson, Nicholas, DeAntonis, Christine M., Frassetto, Andrea, Hanahoe, Erin, Ketova, Tatiana, Jacquinet, Eric, Presnyak, Vladimir, Jain, Ruchi, Marshall, John, Martini, Paolo G.V.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.09.2024
• Subjects: Lipid nanoparticle; Liver; Methylmalonic acid; Methylmalonic acidemia/aciduria; Methylmalonyl-CoA mutase; mRNA therapy; mRNA therapy; Methylmalonic acid; Methylmalonic acidemia/aciduria; Liver; Lipid nanoparticle; Methylmalonyl-CoA mutase
• ISSN: 1096-7192; 1096-7206; 1096-7206
• DOI: 10.1016/j.ymgme.2024.108560

Isolated methylmalonic acidemia/aciduria (MMA) due to MMUT enzyme deficiency is an ultra-rare pediatric disease with high morbidity and mortality, with no approved disease-altering therapies. Previous publications showed that systemic treatment with a codon-optimized mRNA encoding wild-type human MMUT (MMUT) is a promising strategy for treatment of MMA. We developed a second-generation drug product, mRNA-3705, comprised of an mRNA encoding the MMUT enzyme formulated in a lipid nanoparticle (LNP) with incorporation of enhancements over the previous clinical candidate mRNA-3704. Both drug products produced functional MMUT in rat livers when dosed IV, and showed long-term safety and efficacy in two mouse models of MMA. mRNA-3705 produced 2.1–3.4-fold higher levels of hepatic MMUT protein expression than the first-generation drug product mRNA-3704 when given at an identical dose level, which resulted in greater and more sustained reductions in plasma methylmalonic acid. The data presented herein provide comprehensive preclinical pharmacology to support the clinical development of mRNA-3705.